DEEP TRACK CAPITAL LP
Q2 2026 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001856083
· CRD 312459
· SEC-registered investment adviser
$6.9B Reported Value Total
DEEP TRACK CAPITAL, LP reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $8,373,382,671, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $8.4B gross asset value
Hedge Fund: $8.4B
Source: Form ADV filed 2026-03-31
Reported value
$6.9B
Quarter over quarter
+30.9%
Holdings
66
Top-10 concentration
39.6%
Key People
Form ADV owners & control persons
David Eric Kroin
MANAGING MEMBER
Nir Salman Messafi
CHIEF OPERATING AND FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $6.9B |
| Positions | 66 |
| Change in reported value | +12.2% |
| New positions | 18 |
| Exited positions | 14 |
| Position turnover | 40.0% |
| Top-10 concentration | 39.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
66 | $6.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
62 | $6.1B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
53 | $5.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
56 | $3.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
65 | $3.1B |
|
Q1 2025 13F
Filed May 15, 2025
|
69 | $3.1B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
61 | $2.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
69 | $3.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
67 | $3.4B |
|
Q1 2024 13F
Filed May 15, 2024
|
65 | $3.5B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
57 | $3.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
62 | $2.6B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
53 | $2.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
54 | $2.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
57 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
60 | $2.2B |
|
Q2 2022 13F
Filed Aug 12, 2022
|
49 | $1.5B |
|
Q1 2022 13F
Filed May 16, 2022
|
49 | $1.6B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
49 | $1.4B |
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | GH GUARDANT HEALTH INC | $509.1M | 7.41% |
| 2 | IMVT IMMUNOVANT INC | $359.9M | 5.24% |
| 3 | GPCR STRUCTURE THERAPEUTICS INC | $254.4M | 3.7% |
| 4 | PCVX VAXCYTE INC | $250.0M | 3.64% |
| 5 | ALNY ALNYLAM PHARMACEUTICALS INC | $248.3M | 3.61% |
| 6 | MANE VERADERMICS INC | $245.9M | 3.58% |
| 7 | TARS TARSUS PHARMACEUTICALS INC | $230.8M | 3.36% |
| 8 | NUVL NUVALENT INC | $220.2M | 3.21% |
| 9 | ALKS ALKERMES PLC | $209.6M | 3.05% |
| 10 | OCUL OCULAR THERAPEUTIX INC | $193.3M | 2.81% |
| 11 | BMRN BIOMARIN PHARMACEUTICAL INC | $189.3M | 2.75% |
| 12 | NRIX NURIX THERAPEUTICS INC | $187.7M | 2.73% |
| 13 | ORKA ORUKA THERAPEUTICS INC | $183.3M | 2.67% |
| 14 | ALMS ALUMIS INC | $178.6M | 2.6% |
| 15 | IONS IONIS PHARMACEUTICALS INC | $174.4M | 2.54% |
| 16 | CMPS COMPASS PATHWAYS PLC | $172.1M | 2.5% |
| 17 | VERA VERA THERAPEUTICS INC | $171.6M | 2.5% |
| 18 | AXSM AXSOME THERAPEUTICS INC. | $171.3M | 2.49% |
| 19 | GMAB GENMAB A/S | $155.2M | 2.26% |
| 20 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $136.3M | 1.98% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.